Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
Strand, Vibeke
McInnes, Iain
Mease, Philip
Nash, Peter
Thom, Howard
Kalyvas, Chrysostomos
Hunger, Matthias
Gandhi, Kunal
Pricop, Luminita
Jugl, Steffen
Choy, Ernest
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location
License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Abstract

Aim: To compare secukinumab with infliximab in biologic-naive patients with psoriatic arthritis using matching-adjusted indirect comparison. Patients & methods: Individual patient baseline data for secukinumab were matched to published aggregate data for infliximab by key baseline characteristics, with matching weights determined by logistic regression, and used to recalculate American College of Rheumatology (ACR) responses for secukinumab, for comparison with infliximab. Results: There were no differences in outcomes between secukinumab and infliximab at weeks 6/8 and 14/16. At weeks 24 and 54/52, ACR 20 responses were higher with secukinumab 150 mg than infliximab. At week 54/52, ACR 20/50 responses were higher for secukinumab 300 mg than infliximab. Conclusion: In the mid to long term, patients receiving secukinumab were more likely to achieve ACR 20/50 responses than those receiving infliximab.

Journal Title
Journal of Comparative Effectiveness Research
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
© 2019 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Rheumatology and arthritis
Immunology
Science & Technology
Life Sciences & Biomedicine
Health Care Sciences & Services
comparative effectiveness
infliximab
Persistent link to this record
Citation
Strand, V; McInnes, I; Mease, P; Nash, P; Thom, H; Kalyvas, C; Hunger, M; Gandhi, K; Pricop, L; Jugl, S; Choy, E, Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis, Journal of Comparative Effectiveness Research, 2019, 8 (7), pp. 497-510
Collections